Progressive Supranuclear Palsy (PSP) is a brain disease affecting movement, balance, and eye movements. The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a research project studying a drug called LM11A-31 to see if it helps people with PSP. This is a multi-center trial, meaning it happens in different places, and it's randomized, so participants have an equal chance of receiving the drug or a placebo (a pill with no medicine). To join, you must have had PSP symptoms for 5 years or less and be able to walk at least 10 steps with minimal help.

• **Study Duration:** Participants will be in the study as long as the Master Protocol is active.
• **Visits Needed:** Participants must attend regular assessments during the study.
• **Risks:** Potential risks include side effects of the drug, and health checks like MRIs and blood tests are required.

Check if you meet the criteria, such as not having certain health conditions or pregnancy, before joining. Always consult with a healthcare provider to understand the risks and benefits of participating in this trial.